Back To Search Results


Editor: Omar A. Iqbal Updated: 1/15/2023 12:02:35 PM


Azithromycin is a broad-spectrum macrolide antimicrobial and is among the most prescribed antimicrobial drugs in the United States. It is a derivative of erythromycin with greatly enhanced activity against gram-negative bacteria (including Enterobacteriaceae) and provides coverage of many gram-positive organisms.[1][2] 

  • As an inhibitor of bacterial protein synthesis (rather than a peptidoglycan cell-wall inhibitor like beta-lactam agents), azithromycin is effective against many “atypical” bacteria such as chlamydiae (e.g., Chlamydia trachomatis and Chlamydophila psittaci), legionella (i.e., Legionella pneumophila), mycoplasma (e.g., Mycoplasma pneumoniae), and mycobacteria (e.g., Mycobacterium avium).[3] 
  • Together with its activity against Streptococcus pneumoniae, Hemophilus influenzae, and Moraxella catarrhalis, azithromycin is indicated—and FDA approved—for the treatment of community-acquired pneumonia (CAP).[4]  
  • Azithromycin also has approval for use in other upper respiratory infectious processes, including acute otitis media and acute exacerbation of chronic obstructive pulmonary disease (COPD).[5]
  • Additionally, azithromycin has approval for the treatment of pharyngitis caused by Streptococcus pyogenes as an alternative to a beta-lactam agent; skin or skin structure infection due to S. pyogenes, Streptococcus agalactiae, or Staphylococcus aureus;  M. avium complex (MAC) infection treatment and prophylaxis for patients with advanced acquired immunodeficiency syndrome (AIDS); and sexually transmitted infections including chlamydia, gonococcal disease, chancroid (caused by Hemophilus ducreyi), and Mycoplasma genitalium.[6][7][8][9][10]
  • Azithromycin also has efficacy against some protozoal organisms such as Babesia sp. (e.g., B. microti), Plasmodium sp. (i.e., malaria), and Toxoplasma gondii and is sometimes used off-label for the treatment of these parasitic diseases in combination with antiprotozoal drugs (e.g., atovaquone).[11][12][13]
  • The role of azithromycin in the treatment of viral infections, including the respiratory syncytial virus and novel coronavirus SARS-CoV-2, is indeterminate.[14][15][16][17][18][17]
  • Lastly, azithromycin is also used off-label as long-term prophylaxis for bronchiolitis obliterans (BO) in patients who have undergone lung transplantation.[19]

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Like other macrolide antimicrobials, azithromycin binds to the 23S portion of the 50S bacterial ribosomal subunit. It inhibits bacterial protein synthesis by preventing the transit of aminoacyl-tRNA and the growing protein through the ribosome. Compared to erythromycin, azithromycin is less prone to disassociation from the gram-negative ribosome, conferring its greater efficacy against gram-negative pathogens.[20] Like other macrolides and protein-synthesis inhibitors, azithromycin primarily acts as a bacteriostatic agent, meaning it inhibits bacterial growth rather than directly killing organisms.  However, especially at higher doses, azithromycin has been shown to have a bactericidal effect against certain bacteria, such as streptococci and H. influenzae.[21][22]

Pharmacokinetically, azithromycin rapidly moves from the bloodstream into tissues and, once there, readily crosses cellular membranes, allowing efficacy against intracellular pathogens.[20][22] In non-bacterial organisms (i.e., apicomplexan parasites such as Babesia sp., Plasmodium sp., and Toxoplasma sp.), azithromycin inhibits the 50S ribosome found in the parasite apicoplast, an endosymbiosis-derived organelle with bacteria-like protein-synthesis machinery that performs critical metabolic functions.[23][24]

In addition to azithromycin’s antimicrobial activity, it is also a potent immunomodulator that has been shown to markedly reduce airway neutrophilia, IL-8 gene expression, and C-reactive protein levels in lung transplant recipients.[25] Azithromycin has in vitro antiviral properties, which has created interest in the experimental treatment of SARS-CoV-2. By inducing the expression of RIG-I-like helicases, azithromycin enhanced the rhinovirus-induced expression of interferons in cultured cells of  COPD patients but not in cultured cells of healthy patients in vitro.[26]


Azithromycin is available for both oral and parenteral (intravenous) administration. The extended-release formulation of azithromycin has been discontinued. The usual dose is 250 mg or 500 mg, given once daily for 3 to 5 days, and in severe infections, a higher dose is used. A single dose is occasionally used at 30 mg/kg for otitis media and at 1 g for adults with Chlamydia.

  • Oral formulations include tablets (250 mg, 500 mg), packets (1 gram dissolved in ¼ cup or 60 ml of water), and suspension for reconstitution (100 mg/5 ml, 200 mg/5 ml). Dosing can be administered with or without food.
  • Intravenous (IV) azithromycin is available in a 500 mg preservative-free solution for reconstitution. It should be infused over at least 60 minutes, and azithromycin administration should not be via intramuscular injection or IV bolus.
  • The ophthalmic solution (1%) is available in a 2.5 ml bottle which is used in bacterial conjunctivitis.

Azithromycin demonstrates excellent tissue penetration and intracellular accumulation. Metabolism is hepatic, and excretion is mainly biliary.[27] Its long half-life and extensive tissue and intracellular distribution permit once-daily dosing and a shorter course of treatment than other antimicrobials (e.g., treatment of chlamydia infection with a single administration of 1 g of azithromycin versus 100 mg of doxycycline twice daily for seven days).

Azithromycin may be administered to patients with renal disease or failure without regard for creatinine clearance. No dose adjustment is usually necessary.[28]

Adverse Effects

Azithromycin is generally regarded as a safe antimicrobial agent, and only a few patients discontinue azithromycin due to adverse effects.[29] It is also considered to be safer and with fewer cardiac adverse effects than other macrolides (i.e., erythromycin and clarithromycin).

  • Azithromycin, like other macrolides, can cause QTc prolongation and has been associated with torsades de pointes and polymorphic ventricular tachycardia.[30] In a large retrospective cohort study, azithromycin use correlated with a small but significant absolute increase in cardiovascular death as well as an increased risk of cardiovascular death relative to amoxicillin. These results were most pronounced among those patients with the highest baseline cardiovascular risk.[30] However, another large cohort study failed to detect an increased risk of death from cardiovascular causes in a population of young and middle-aged adults.[31] 
  • Azithromycin is also rarely associated with hepatotoxicity, consisting mainly of hepatocellular injury within 1 to 3 weeks of medication use. Clinical features of hepatotoxicity include cholestatic jaundice and elevated transaminase concentrations.[32]
  • Like other macrolides, gastrointestinal adverse effects such as nausea and diarrhea are commonly reported for azithromycin. All macrolides exhibit dose-dependent activation of intestinal motilin receptors, which stimulate gastric motility. (Clinicians widely prescribe erythromycin for the treatment of gastroparesis due to this mechanism.)[33]
  • Life-threatening hypersensitivity reactions to azithromycin, such as anaphylaxis and Stevens-Johnson syndrome (SJS), are extremely unusual.[34][35] 
  • Macrolides also correlate with the development of Clostridioides difficile infection, but to a lesser degree than other common antimicrobial classes (e.g., clindamycin, fluoroquinolones, and cephalosporins).[36][37][38]


  • Azithromycin is contraindicated in patients with a history of severe hypersensitivity (e.g., anaphylaxis or SJS) to azithromycin or another macrolide antimicrobial. In addition, clinicians should be cautious regarding the concomitant use of azithromycin and other medications that prolong the QTc interval (e.g., antipsychotics).
  • Azithromycin is contraindicated for patients taking the first-generation antipsychotic pimozide. Macrolide antimicrobials inhibit CYP3A4, the same cytochrome that metabolizes pimozide; concomitant use of azithromycin with pimozide can cause dangerous plasma concentrations of pimozide, leading to QTc prolongation and, potentially, lethal arrhythmias. While azithromycin is a poor inhibitor of CYP3A4 relative to other macrolides, avoidance of this interaction is still advisable.[39][40]
  • Additionally, azithromycin is an inhibitor of p-glycoprotein/ABCB1, a cell membrane glycoprotein transporter. Drugs that are substrates of P-glycoprotein, particularly those that are also substrates of CYP3A4, may represent a relative contraindication to azithromycin. Examples include colchicine and small-molecule calcitonin gene-related peptide (CGRP) antagonists.[41][42]
  • Azithromycin effectively preserves FEV and ameliorates bronchiolitis obliterans (BO) with no effect on overall survival in lung transplant patients; however, a study comparing azithromycin with placebo for the prevention of BO in hematopoietic stem cell transplant (HSCT) recipients demonstrated decreased BO-free and overall survival with azithromycin.[43] Hence, long-term azithromycin prophylaxis in HSCT recipients is inadvisable.


Most courses of treatment with azithromycin are short, and adverse effects requiring therapy adjustment or discontinuation of azithromycin are rare.[29] Azithromycin should be immediately discontinued if signs of hepatotoxicity develop (e.g., jaundice or elevated transaminases). For patients receiving long-term azithromycin prophylaxis (e.g., AIDS patients for MAC prophylaxis or lung transplant recipients for BO prophylaxis), many patients experience gastrointestinal adverse effects, especially at higher doses (e.g., 600 mg or 1200 mg). In these patients, reduction of the dose or twice-daily dosing may be a consideration.[44][45]


Azithromycin, like other macrolides, is associated with QTc prolongation. Particularly in patients with a known history of QTc interval perturbation, cardiac arrhythmia, or concomitant use of other medications associated with QTc prolongation, azithromycin can result in dangerous or potentially lethal arrhythmias such as torsades de pointes. In animal studies, although azithromycin was associated with similar QTc prolongation compared to other macrolides, azithromycin seemed to have a smaller proarrhythmic effect.[46]

While significant hepatoxicity resulting from azithromycin is relatively rare, macrolides are an established cause of mixed hepatocellular/cholestatic drug-induced liver injury. With prompt discontinuation of azithromycin, liver injury is almost always reversible with minimal residual impairment. Often, azithromycin-induced hepatotoxicity has associated immunoallergic features such as rash, fever, and eosinophilia. Severe forms of immunoallergic reaction, such as anaphylaxis, SJS, and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare.[47]

Gastrointestinal toxicity is common but typically mild, and most patients complete the prescribed course of azithromycin. This toxicity stems largely from azithromycin’s activation of pro-motility receptors in the gastrointestinal tract.

Enhancing Healthcare Team Outcomes

Although azithromycin is a generally well-tolerated, efficacious antimicrobial agent with many clinical indications, it is commonly inappropriately prescribed, particularly in the primary care setting. Several large retrospective cohort studies that demonstrated high levels of inappropriate antimicrobial prescribing overall singled out azithromycin as the most frequently misused drug.[48][49][50][51][52] [Level 1][Level 3]

Azithromycin is frequently prescribed when there is no clinical indication for antimicrobials and in many instances in which azithromycin is not first-line therapy (e.g., acute otitis media).[48][52] [Level 1][Level 3]

Azithromycin is a frequent antimicrobial therapy prescribed in situations in which a narrow-spectrum beta-lactam (e.g., amoxicillin) is the indicated first-line therapy (e.g., acute otitis media).[48] [Level 1] Increasing levels of resistance to azithromycin, particularly among S. pneumoniae isolates, make the widespread use of azithromycin for upper respiratory illness particularly concerning.[53][54] [Level 3] Broad-spectrum antimicrobial use for upper respiratory infection is also associated with increased rates of adverse effects compared with narrow-spectrum agents.[55] [Level 3]

One possible association with high rates of azithromycin prescription is patient-reported penicillin allergy.[56] [Level 1] Macrolides, particularly azithromycin, are preferred to beta-lactam drugs for many clinical indications. Researchers found 12.8% of patients in a large electronic medical records database have a penicillin allergy listed in one large cohort.[57] [Level 3] Patients with a reported penicillin allergy are as much as four times more likely to be prescribed a macrolide antimicrobial.[56] [Level 1] However, a detailed history of a patient’s adverse reaction(s) to penicillin, paying close attention to features suggestive of IgE-mediated hypersensitivity (e.g., urticaria, anaphylaxis), is often sufficient to clarify, and possibly remove, a listing of penicillin allergy.[58] [Level 5] Patients with more concerning histories may be administered allergy testing or referred to an allergy specialist. Lastly, providers should be aware of the low cross-reactivity rates with cephalosporins—especially third- and higher-generation agents—and other beta-lactams in penicillin allergy.[59] [Level 1]

Healthcare professionals in many different roles can contribute to the appropriate use of azithromycin and all antimicrobial agents. MDs, DOs, NPs, and PAs should prescribe azithromycin judiciously and make use of available evidence and society guidelines. Clinicians working with and/or supervising non-physician prescribers should ensure that all prescriptions accord with evidence and guideline-based practice.[50] [Level 3] Additionally, patients requesting antimicrobial therapy when it is not necessary, or sharing concerns about drug allergies, should be provided with education and appropriate follow-up. Nurses can play an essential role in addressing patient questions and facilitating continuity of care. Pharmacists are an invaluable resource for helping providers select the most appropriate antimicrobial agent, dosing, and duration of treatment. They can also help providers and patients avoid interactions between azithromycin and other drugs that affect the QTc interval.

While azithromycin is a safe and effective antimicrobial drug, practitioners must take care to prescribe it appropriately. Not only does the appropriate choice of antimicrobial therapy enhance treatment and support public health, but it avoids placing patients at unnecessary risk of adverse effects.



Girard AE,Girard D,English AR,Gootz TD,Cimochowski CR,Faiella JA,Haskell SL,Retsema JA, Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrobial agents and chemotherapy. 1987 Dec;     [PubMed PMID: 2830841]

Level 3 (low-level) evidence


Retsema J,Girard A,Schelkly W,Manousos M,Anderson M,Bright G,Borovoy R,Brennan L,Mason R, Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrobial agents and chemotherapy. 1987 Dec;     [PubMed PMID: 2449865]


Bakheit AH,Al-Hadiya BM,Abd-Elgalil AA, Azithromycin. Profiles of drug substances, excipients, and related methodology. 2014     [PubMed PMID: 24794904]

Level 3 (low-level) evidence


Dekate PS,Mathew JL,Jayashree M,Singhi SC, Acute community acquired pneumonia in emergency room. Indian journal of pediatrics. 2011 Sep     [PubMed PMID: 21541648]


Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacology & therapeutics. 2014 Aug:143(2):225-45. doi: 10.1016/j.pharmthera.2014.03.003. Epub 2014 Mar 11     [PubMed PMID: 24631273]


Pacifico L,Scopetti F,Ranucci A,Pataracchia M,Savignoni F,Chiesa C, Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Antimicrobial agents and chemotherapy. 1996 Apr;     [PubMed PMID: 8849215]

Level 1 (high-level) evidence


Amaya-Tapia G,Aguirre-Avalos G,Andrade-Villanueva J,Peredo-González G,Morfín-Otero R,Esparza-Ahumada S,Rodríguez-Noriega E, Once-daily azithromycin in the treatment of adult skin and skin-structure infections. The Journal of antimicrobial chemotherapy. 1993 Jun;     [PubMed PMID: 8396084]

Level 1 (high-level) evidence


Daley CL, Mycobacterium avium Complex Disease. Microbiology spectrum. 2017 Apr     [PubMed PMID: 28429679]


Waugh MA, Azithromycin in gonorrhoea. International journal of STD & AIDS. 1996     [PubMed PMID: 8652723]


Jensen JS,Cusini M,Gomberg M,Moi H, 2016 European guideline on Mycoplasma genitalium infections. Journal of the European Academy of Dermatology and Venereology : JEADV. 2016 Oct     [PubMed PMID: 27505296]


Krause PJ,Lepore T,Sikand VK,Gadbaw J Jr,Burke G,Telford SR 3rd,Brassard P,Pearl D,Azlanzadeh J,Christianson D,McGrath D,Spielman A, Atovaquone and azithromycin for the treatment of babesiosis. The New England journal of medicine. 2000 Nov 16;     [PubMed PMID: 11078770]

Level 3 (low-level) evidence


Dunne MW,Singh N,Shukla M,Valecha N,Bhattacharyya PC,Dev V,Patel K,Mohapatra MK,Lakhani J,Benner R,Lele C,Patki K, A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. The Journal of infectious diseases. 2005 May 15;     [PubMed PMID: 15838784]

Level 1 (high-level) evidence


Shiojiri D,Kinai E,Teruya K,Kikuchi Y,Oka S, Combination of Clindamycin and Azithromycin as Alternative Treatment for Toxoplasma gondii Encephalitis. Emerging infectious diseases. 2019 Apr;     [PubMed PMID: 30882331]


Gautret P,Lagier JC,Parola P,Hoang VT,Meddeb L,Mailhe M,Doudier B,Courjon J,Giordanengo V,Vieira VE,Dupont HT,Honoré S,Colson P,Chabrière E,La Scola B,Rolain JM,Brouqui P,Raoult D, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020 Mar 20;     [PubMed PMID: 32205204]

Level 2 (mid-level) evidence


Gautret P,Lagier JC,Parola P,Hoang VT,Meddeb L,Sevestre J,Mailhe M,Doudier B,Aubry C,Amrane S,Seng P,Hocquart M,Eldin C,Finance J,Vieira VE,Tissot-Dupont HT,Honoré S,Stein A,Million M,Colson P,La Scola B,Veit V,Jacquier A,Deharo JC,Drancourt M,Fournier PE,Rolain JM,Brouqui P,Raoult D, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel medicine and infectious disease. 2020 Apr 11;     [PubMed PMID: 32289548]

Level 2 (mid-level) evidence


Arabi YM,Deeb AM,Al-Hameed F,Mandourah Y,Almekhlafi GA,Sindi AA,Al-Omari A,Shalhoub S,Mady A,Alraddadi B,Almotairi A,Al Khatib K,Abdulmomen A,Qushmaq I,Solaiman O,Al-Aithan AM,Al-Raddadi R,Ragab A,Al Harthy A,Kharaba A,Jose J,Dabbagh T,Fowler RA,Balkhy HH,Merson L,Hayden FG, Macrolides in critically ill patients with Middle East Respiratory Syndrome. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2019 Apr;     [PubMed PMID: 30690213]


Pinto LA,Pitrez PM,Luisi F,de Mello PP,Gerhardt M,Ferlini R,Barbosa DC,Daros I,Jones MH,Stein RT,Marostica PJ, Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial. The Journal of pediatrics. 2012 Dec;     [PubMed PMID: 22748516]

Level 1 (high-level) evidence


Echeverría-Esnal D,Martin-Ontiyuelo C,Navarrete-Rouco ME,De-Antonio Cuscó M,Ferrández O,Horcajada JP,Grau S, Azithromycin in the treatment of COVID-19: a review. Expert review of anti-infective therapy. 2021 Feb;     [PubMed PMID: 32853038]


Vos R,Vanaudenaerde BM,Verleden SE,De Vleeschauwer SI,Willems-Widyastuti A,Van Raemdonck DE,Schoonis A,Nawrot TS,Dupont LJ,Verleden GM, A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. The European respiratory journal. 2011 Jan;     [PubMed PMID: 20562124]

Level 1 (high-level) evidence


Goldman RC,Fesik SW,Doran CC, Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria. Antimicrobial agents and chemotherapy. 1990 Mar;     [PubMed PMID: 2159256]


Jelić D,Antolović R, From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials. Antibiotics (Basel, Switzerland). 2016 Sep 1;     [PubMed PMID: 27598215]


Neu HC, Clinical microbiology of azithromycin. The American journal of medicine. 1991 Sep 12;     [PubMed PMID: 1656736]

Level 3 (low-level) evidence


Sidhu AB,Sun Q,Nkrumah LJ,Dunne MW,Sacchettini JC,Fidock DA, In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. The Journal of biological chemistry. 2007 Jan 26;     [PubMed PMID: 17110371]

Level 3 (low-level) evidence


Biddau M,Sheiner L, Targeting the apicoplast in malaria. Biochemical Society transactions. 2019 Aug 30;     [PubMed PMID: 31383817]


Verleden GM,Vanaudenaerde BM,Dupont LJ,Van Raemdonck DE, Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. American journal of respiratory and critical care medicine. 2006 Sep 1;     [PubMed PMID: 16741151]


Menzel M,Akbarshahi H,Bjermer L,Uller L, Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Scientific reports. 2016 Jun 28;     [PubMed PMID: 27350308]


Drew RH,Gallis HA, Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy. 1992;     [PubMed PMID: 1319048]


Höffler D,Koeppe P,Paeske B, Pharmacokinetics of azithromycin in normal and impaired renal function. Infection. 1995 Nov-Dec;     [PubMed PMID: 8655206]


Ioannidis JP,Contopoulos-Ioannidis DG,Chew P,Lau J, Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. The Journal of antimicrobial chemotherapy. 2001 Nov;     [PubMed PMID: 11679557]

Level 1 (high-level) evidence


Ray WA,Murray KT,Hall K,Arbogast PG,Stein CM, Azithromycin and the risk of cardiovascular death. The New England journal of medicine. 2012 May 17;     [PubMed PMID: 22591294]

Level 2 (mid-level) evidence


Svanström H,Pasternak B,Hviid A, Use of azithromycin and death from cardiovascular causes. The New England journal of medicine. 2013 May 2;     [PubMed PMID: 23635050]

Level 2 (mid-level) evidence


Martinez MA,Vuppalanchi R,Fontana RJ,Stolz A,Kleiner DE,Hayashi PH,Gu J,Hoofnagle JH,Chalasani N, Clinical and histologic features of azithromycin-induced liver injury. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015 Feb;     [PubMed PMID: 25111234]


Barboza JL,Okun MS,Moshiree B, The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. Expert opinion on pharmacotherapy. 2015;     [PubMed PMID: 26374094]

Level 3 (low-level) evidence


Nappe TM,Goren-Garcia SL,Jacoby JL, Stevens-Johnson syndrome after treatment with azithromycin: an uncommon culprit. The American journal of emergency medicine. 2016 Mar;     [PubMed PMID: 26194400]


Mori F,Pecorari L,Pantano S,Rossi ME,Pucci N,De Martino M,Novembre E, Azithromycin anaphylaxis in children. International journal of immunopathology and pharmacology. 2014 Jan-Mar;     [PubMed PMID: 24674687]

Level 3 (low-level) evidence


Dial S,Kezouh A,Dascal A,Barkun A,Suissa S, Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2008 Oct 7;     [PubMed PMID: 18838451]

Level 2 (mid-level) evidence


Kuntz JL,Chrischilles EA,Pendergast JF,Herwaldt LA,Polgreen PM, Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC infectious diseases. 2011 Jul 15;     [PubMed PMID: 21762504]

Level 2 (mid-level) evidence


Deshpande A,Pasupuleti V,Thota P,Pant C,Rolston DD,Sferra TJ,Hernandez AV,Donskey CJ, Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. The Journal of antimicrobial chemotherapy. 2013 Sep;     [PubMed PMID: 23620467]

Level 1 (high-level) evidence


Westphal JF, Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. British journal of clinical pharmacology. 2000 Oct;     [PubMed PMID: 11012550]


Flockhart DA,Drici MD,Kerbusch T,Soukhova N,Richard E,Pearle PL,Mahal SK,Babb VJ, Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. Journal of clinical psychopharmacology. 2000 Jun;     [PubMed PMID: 10831018]

Level 3 (low-level) evidence


Bouquié R,Deslandes G,Renaud C,Dailly E,Haloun A,Jolliet P, Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2011 Jan     [PubMed PMID: 21169852]

Level 3 (low-level) evidence


Terkeltaub RA,Furst DE,Digiacinto JL,Kook KA,Davis MW, Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis and rheumatism. 2011 Aug     [PubMed PMID: 21480191]


Bergeron A,Chevret S,Granata A,Chevallier P,Vincent L,Huynh A,Tabrizi R,Labussiere-Wallet H,Bernard M,Chantepie S,Bay JO,Thiebaut-Bertrand A,Thepot S,Contentin N,Fornecker LM,Maillard N,Risso K,Berceanu A,Blaise D,Peffault de La Tour R,Chien JW,Coiteux V,Socié G, Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. JAMA. 2017 Aug 8;     [PubMed PMID: 28787506]

Level 1 (high-level) evidence


Brown BA,Griffith DE,Girard W,Levin J,Wallace RJ Jr, Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1997 May;     [PubMed PMID: 9142801]


Koletar SL,Berry AJ,Cynamon MH,Jacobson J,Currier JS,MacGregor RR,Dunne MW,Williams DJ, Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. Antimicrobial agents and chemotherapy. 1999 Dec;     [PubMed PMID: 10582873]

Level 1 (high-level) evidence


Milberg P,Eckardt L,Bruns HJ,Biertz J,Ramtin S,Reinsch N,Fleischer D,Kirchhof P,Fabritz L,Breithardt G,Haverkamp W, Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. The Journal of pharmacology and experimental therapeutics. 2002 Oct;     [PubMed PMID: 12235254]

Level 3 (low-level) evidence


Hoofnagle JH,Björnsson ES, Drug-Induced Liver Injury - Types and Phenotypes. The New England journal of medicine. 2019 Jul 18;     [PubMed PMID: 31314970]


Fleming-Dutra KE,Demirjian A,Bartoces M,Roberts RM,Taylor TH Jr,Hicks LA, Variations in Antibiotic and Azithromycin Prescribing for Children by Geography and Specialty-United States, 2013. The Pediatric infectious disease journal. 2018 Jan;     [PubMed PMID: 28746259]


Chua KP,Fischer MA,Linder JA, Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study. BMJ (Clinical research ed.). 2019 Jan 16;     [PubMed PMID: 30651273]


Shively NR,Buehrle DJ,Clancy CJ,Decker BK, Prevalence of Inappropriate Antibiotic Prescribing in Primary Care Clinics within a Veterans Affairs Health Care System. Antimicrobial agents and chemotherapy. 2018 Aug;     [PubMed PMID: 29967028]


White AT,Clark CM,Sellick JA,Mergenhagen KA, Antibiotic stewardship targets in the outpatient setting. American journal of infection control. 2019 Aug;     [PubMed PMID: 30862373]


Havers FP,Hicks LA,Chung JR,Gaglani M,Murthy K,Zimmerman RK,Jackson LA,Petrie JG,McLean HQ,Nowalk MP,Jackson ML,Monto AS,Belongia EA,Flannery B,Fry AM, Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA network open. 2018 Jun 1;     [PubMed PMID: 30646067]


Critchley IA,Jacobs MR,Brown SD,Traczewski MM,Tillotson GS,Janjic N, Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. Antimicrobial agents and chemotherapy. 2008 Jul;     [PubMed PMID: 18443117]


Karlowsky JA,Thornsberry C,Critchley IA,Jones ME,Evangelista AT,Noel GJ,Sahm DF, Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrobial agents and chemotherapy. 2003 Jun;     [PubMed PMID: 12760850]


Gerber JS,Ross RK,Bryan M,Localio AR,Szymczak JE,Wasserman R,Barkman D,Odeniyi F,Conaboy K,Bell L,Zaoutis TE,Fiks AG, Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections. JAMA. 2017 Dec 19;     [PubMed PMID: 29260224]

Level 2 (mid-level) evidence


Blumenthal KG,Lu N,Zhang Y,Li Y,Walensky RP,Choi HK, Risk of meticillin resistant {i}Staphylococcus aureus{/i} and {i}Clostridium difficile{/i} in patients with a documented penicillin allergy: population based matched cohort study. BMJ (Clinical research ed.). 2018 Jun 27;     [PubMed PMID: 29950489]


Zhou L,Dhopeshwarkar N,Blumenthal KG,Goss F,Topaz M,Slight SP,Bates DW, Drug allergies documented in electronic health records of a large healthcare system. Allergy. 2016 Sep;     [PubMed PMID: 26970431]


Shenoy ES,Macy E,Rowe T,Blumenthal KG, Evaluation and Management of Penicillin Allergy: A Review. JAMA. 2019 Jan 15;     [PubMed PMID: 30644987]


Romano A,Valluzzi RL,Caruso C,Maggioletti M,Quaratino D,Gaeta F, Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. The journal of allergy and clinical immunology. In practice. 2018 Sep - Oct;     [PubMed PMID: 29408440]